Innovus Pharma's AllerVarx(TM) Receives Commercial Approval by Health Canada for the Reduction in Symptoms of Seasonal Allergic Rhinitis

Stock Information for InnovAge Holding Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About InnovAge Holding Corp.

Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals
Innovus Pharma Reports Quarterly Revenue for the Second Quarter 2019 of $6.8 million, a 27.7% Increase from Prior Quarter
Innovus Pharmaceuticals to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 13, 2019
Innovus Pharmaceuticals Announces that its Delta Prime Savings Club E-Commerce Marketplace is on Track for Annual Sales of Approximately $3 million in 2019
Cannabis and OTC Medications Gain Health Canada Approval with Rise of Cannabis/Wellness Market
Innovus Pharmaceuticals Announces Progress in Fulfilling the Regulatory and Manufacturing Steps to Receive Market Authorization for FlutiCare® in Canada
Muscle and Repair Treatments versus Surgery - Europe and Global Markets offer Big Opportunities
Innovus Pharmaceuticals Receives Notification to Market and Sell CarvaNum® for Muscle Recovery in the European Union

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.